NPL 2003

Drug Profile

NPL 2003

Alternative Names: NPL-2003

Latest Information Update: 28 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuropharm
  • Class Anxiolytics
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obsessive-compulsive disorders

Most Recent Events

  • 21 Dec 2011 Autism Therapeutics acquires Neuropharm
  • 21 Dec 2011 Discontinued - Phase-II for Obsessive-compulsive disorders in USA (unspecified route)
  • 12 May 2009 Phase II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top